mac lung disease epidemiology forecast

Key Highlights

• Mycobacterium Avium Complex (MAC) is a group of bacteria responsible for MAC lung disease. The two main species in MAC, Mycobacterium avium and Mycobacterium intracellulare together known as MAI have been recognized for nearly a century. MAC is a major type of nontuberculous mycobacteria (NTM) and the leading cause of NTM lung disease in the US.
• MAC lung disease includes a slow-growing nodular bronchiectatic form seen in older, thin non-smoking women, and a more severe fibrocavitary form with lung cavities, common in smokers and those with emphysema.
• In 2024, the total diagnosed prevalent cases of NTM lung disease were approximately 150,000 in the 7MM.
• In 2024, there were approximately 120,000 total diagnosed prevalent cases of MAC lung disease in the 7MM.
• Among the 7MM, the US accounted for approximately 64%, EU4 and the UK for nearly 8%, and Japan for around 28% of the total diagnosed prevalent cases of MAC lung disease in 2024.

DelveInsight’s “MAC Lung Disease – Epidemiology Forecast – 2034” report delivers an in-depth understanding of MAC lung disease historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The table given below further depicts the key segments provided in the report:

MAC Lung Disease: Disease Understanding

MAC Lung Disease Overview, and Diagnosis

According to the American Lung Association, MAC lung disease is an infection caused by a group of bacteria known as the MAC. MAC, a subset of NTM, is the most common cause of NTM-related lung disease in the US

MAC lung disease is characterized by symptoms such as fatigue, persistent cough, and shortness of breath, night sweats, hemoptysis, and weight loss. MAC infections can occur in both immunocompetent and immunocompromised individuals.

Diagnosis of MAC lung disease involves clinical evaluation, imaging (X-rays or CT scans) to detect lung changes, and sputum cultures to confirm MAC bacteria often requiring multiple samples. If results are inconclusive, bronchoscopy may be used for direct lung examination.

MAC Lung Disease Epidemiology

The MAC lung disease epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of NTM lung disease, total diagnosed prevalent cases of MAC lung disease, gender-specific diagnosed prevalent cases of NTM lung disease, and, species-specific diagnosed prevalent cases of NTM lung disease in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.

• In 2024, species-specific diagnosed prevalent cases of NTM lung disease included approximately 120,000 cases of MAC, 5,500 cases of Mycobacteroides abscessus, and 27,000 cases of other species in the 7MM.
• In 2024, the US reported the highest number of diagnosed prevalent cases of NTM lung disease, with approximately 95,000 cases, in the 7MM.
• In 2024, Germany reported the highest number of diagnosed prevalent cases of MAC lung disease among the EU4 countries and the UK, with nearly 2,600 cases. Italy and France followed, each with approximately 2,100 cases. In contrast, Spain had the lowest prevalence, recording around 700 cases.
• In 2024, Japan reported nearly 33,000 diagnosed prevalent cases of MAC lung disease,
• In 2024, the gender-specific diagnosed prevalent cases of NTM lung disease in the US were approximately 40,000 for males and 55,000 for females.

Scope of the Report      

• The report covers a segment of an executive summary, and a descriptive overview MAC lung disease explaining its causes, signs and symptoms, pathogenesis.
• Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
• A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.

MAC Lung Disease Report Insights

• Patient Population
• Country-wise Epidemiology Distribution

MAC Lung Disease Report Key Strengths

• Ten-year Forecast
• The 7MM Coverage
• MAC lung disease Epidemiology Segmentation

MAC Lung Disease Report Assessment

• Epidemiology Segmentation
• Current Diagnostic Practices

FAQs

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of MAC lung disease? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to MAC lung disease?
• What is the historical and forecasted MAC lung disease patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What is the diagnostic pattern of MAC Lung Disease?
• Which clinical factors will affect MAC Lung Disease?
• Which factors will affect the increase in the diagnosis of MAC Lung Disease?

Reasons to buy

• Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the change in MAC lung disease cases in varying geographies over the coming years.
• A detailed overview of total diagnosed prevalent cases of NTM lung disease, total diagnosed prevalent cases of MAC lung disease, gender-specific diagnosed prevalent cases of NTM lung disease, and, species-specific diagnosed prevalent cases of NTM lung disease is included.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.